The NovaCode Advantage
Our unique strengths position us at the forefront of therapeutic innovation
Our Core Advantages
Pioneering Platforms
Innovative discovery and delivery systems.
Decades of Expertise
35+ years of continuous scientific innovation.
Targeted Solutions
Addressing unreachable disease drivers effectively.
Collaborative Approach
Partnering to accelerate medical breakthroughs.
Our Solutions
NovaCode Bio aims to pioneer a scalable, AI-driven platform for peptide discovery and delivery, leveraging non-canonical amino acids and advanced automation to target intracellular and CNS challenges, delivering precise peptide-based therapies across the blood-brain barrier to transform medicine.
Rapidly generate and optimize multi-cyclic peptide libraries.
Dramatically accelerate lead identification, reduce downstream attrition, and enable scalable, end-to-end automation.
Achieve targeted intracellular and blood-brain barrier penetration via precision-engineered nanocarriers.
NovaCode Bio Drug Discovery System
Four Pillars of Innovation
Non-canonical Amino Acids Unlock Novel Chemical Space
We employ over 200 non-canonical amino acids site-specifically incorporated into evolving peptide chains, creating unique functional handles and conformational constraints that enhance target.
200+ amino acidsMulti-cyclic Peptide Libraries for Enhanced Potency & Stability
Our platform constructs vast multi-cyclic peptide libraries via macrocyclization chemistries, delivering high screening success rates, enabling rapid hit discovery against intracellular and CNS targets in as little as weeks--versus years by traditional methods.
Weeks vs YearsPrecision Nano-Delivery for Intracellular & CNS Access
Early automated, AI-centered integrable nanocarriers equipped with endosomal-escape and receptor-mediated-transport modules, achieving efficient cytosolic delivery and blood-brain-barrier transcytosis in preclinical models.
CNS AccessFully Automated, AI-Accelerated Workflows
End-to-end automated system integrates combinatorial synthesis, high-throughput on-site in vitro and cellular assays, and closed-loop generative-AI design to optimize sequences for potency, permeability, and safety in real time.
AI-DrivenSuccesses of the platform - library screens to clinical trials
NCT03804424
64Cu-LLP2A PET Imaging in Diagnosing Patients with Multiple Myeloma.
NCT03197623
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women with Osteopenia Secondary to Corticosteroids.
NCT06173349
Screening of OBOC peptide library identified the bladder cancer-targeting peptide ligand PLZ4. PLZ4-conjugated telodendrimer self-assembled into nanomicelle and efficiently loaded PTX.
Ready to Explore Our Innovation?
Discover how our revolutionary platforms can transform therapeutic development